In humans, homocysteine (Hcy) is employed to monitor renal, cardiovascular, and other diseases and their complications. The aim of the current study was to define the analytical performances of an enzymatic method not yet validated in dogs for measuring homocysteine, and to assess the possible clinical usefulness of Hcy measurement. Using conventional approaches, the analytical performances were investigated by assessing, imprecision, inaccuracy, and interference of hemoglobin, triglycerides, and bilirubin. The possible clinical usefulness of Hcy determination was assessed by comparing the results of healthy dogs (n 5 8) with those of dogs with heart disease (n 5 10), inflammation (n 5 6), gastrointestinal disorders (n 5 7), neoplasia (n 5 8), renal failure (n 5 4), trauma (n 5 7), and other miscellaneous diseases (n 5 6). Preliminary evaluation of this enzymatic method showed it to be precise at Hcy levels close to or higher than the values in dogs with renal or cardiac disorders that had the highest Hcy levels. By contrast, at low Hcy levels, which were recorded basically in control dogs, the method suffers from high imprecision. The sample of choice is serum. The use of icteric samples should be avoided, while hemoglobin and lipids have only a minor effect on Hcy measurement. In conclusion, the enzymatic method employed in the current study provides useful information in dogs and could be used to monitor cardiac and renal disorders, in which Hcy concentrations are elevated.

Homocysteine measurement by an enzymatic method and potential role of homocysteine as a biomarker in dogs / S. Rossi, G. Rossi, A. Giordano, S. Paltrinieri. - In: JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION. - ISSN 1040-6387. - 20:5(2008), pp. 644-649.

Homocysteine measurement by an enzymatic method and potential role of homocysteine as a biomarker in dogs

S. Rossi
Primo
;
G. Rossi
Secondo
;
A. Giordano
Penultimo
;
S. Paltrinieri
Ultimo
2008

Abstract

In humans, homocysteine (Hcy) is employed to monitor renal, cardiovascular, and other diseases and their complications. The aim of the current study was to define the analytical performances of an enzymatic method not yet validated in dogs for measuring homocysteine, and to assess the possible clinical usefulness of Hcy measurement. Using conventional approaches, the analytical performances were investigated by assessing, imprecision, inaccuracy, and interference of hemoglobin, triglycerides, and bilirubin. The possible clinical usefulness of Hcy determination was assessed by comparing the results of healthy dogs (n 5 8) with those of dogs with heart disease (n 5 10), inflammation (n 5 6), gastrointestinal disorders (n 5 7), neoplasia (n 5 8), renal failure (n 5 4), trauma (n 5 7), and other miscellaneous diseases (n 5 6). Preliminary evaluation of this enzymatic method showed it to be precise at Hcy levels close to or higher than the values in dogs with renal or cardiac disorders that had the highest Hcy levels. By contrast, at low Hcy levels, which were recorded basically in control dogs, the method suffers from high imprecision. The sample of choice is serum. The use of icteric samples should be avoided, while hemoglobin and lipids have only a minor effect on Hcy measurement. In conclusion, the enzymatic method employed in the current study provides useful information in dogs and could be used to monitor cardiac and renal disorders, in which Hcy concentrations are elevated.
Biomarker; Dogs; Enzymatic method; Heart disease; Homocysteine; Renal failure
Settore VET/03 - Patologia Generale e Anatomia Patologica Veterinaria
2008
Article (author)
File in questo prodotto:
File Dimensione Formato  
Rossi S. et al._JVDI.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 434.38 kB
Formato Adobe PDF
434.38 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/59717
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact